ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

LIXT Lixte Biotechnology Holdings Inc

2,82
-0,0621 (-2,15%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Lixte Biotechnology Holdings Inc LIXT NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
-0,0621 -2,15% 2,82 06:00:16
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
3,00 2,8735 3,002 2,89 2,8821
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
24.4.202421:25APSMixed Shelf Filing Gives Micro Cap Delayed Boost
27.3.202420:35APSBiotech Steals The Show Following Pre-Clinical Data..
27.3.202413:30GLOBENEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD..
21.3.202413:30GLOBELIXTE Provides Update on Progress with LB-100 as a PP2A..
27.2.202422:59EDGAR2Form 8-K - Current report
27.2.202414:30GLOBEProfessor René Bernards to Present New Pre-Clinical Data on..
26.2.202416:48EDGAR2Form 8-K - Current report
26.2.202414:30GLOBELIXTE Biotechnology Enters into Exclusive Immune Oncology..
29.1.202414:30GLOBEFirst Patient Dosed with LIXTE’s LB-100 and GSK’s..
28.11.202323:21EDGAR2Form 8-K - Current report
13.11.202320:28EDGAR2Form 8-K - Current report
13.11.202314:30GLOBELIXTE Biotechnology Provides Update on Clinical Progress and..
09.11.202323:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
17.10.202323:27EDGAR2Form 8-K - Current report
16.10.202320:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.10.202314:30GLOBELIXTE, Netherlands Cancer Institute, and Oncode Institute to..
10.10.202321:55EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10.10.202321:47EDGAR2Form DEF 14A - Other definitive proxy statements
09.10.202314:30GLOBELIXTE Biotechnology Holdings Announces the Passing of its..
06.10.202302:39EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
06.10.202302:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.10.202300:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.9.202322:05EDGAR2Form PRE 14A - Other preliminary proxy statements
27.9.202312:15EDGAR2Form 8-K - Current report
27.9.202312:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26.9.202314:30GLOBELIXTE Appoints Bas van der Baan as President and Chief..
20.9.202317:20EDGAR2Form 8-K - Current report
20.9.202314:30GLOBELIXTE Biotechnology Announces a Supported Collaborative..
11.8.202322:20EDGAR2Form S-3 - Registration statement under Securities Act of..
09.8.202314:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
21.7.202322:05EDGAR2Form 8-K - Current report
20.7.202322:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20.7.202322:05GLOBELIXTE Biotechnology Announces Closing of $3.5 Million..
20.7.202317:45EDGAR2Form 8-K - Current report
18.7.202314:00GLOBELIXTE Biotechnology Announces Pricing of $3.5 Million..
17.7.202314:30GLOBEPreclinical Results of LIXTE Biotechnology’s Collaboration..
07.7.202320:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.7.202316:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.7.202316:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.7.202316:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.6.202314:30GLOBELIXTE Biotechnology Holdings, Inc. Regains Compliance with..
07.6.202314:30GLOBELIXTE Biotechnology and the Spanish Sarcoma Group Enroll..
02.6.202318:30GLOBELIXTE Biotechnology Holdings, Inc. Announces 1-for-10..
30.5.202314:30GLOBERecently Published Independent Research Reveals New..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock